Clinical Trial Detail

NCT ID NCT02278250
Title An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

Advanced Solid Tumor

Therapies

VX-803

Carboplatin + VX-803

Age Groups: adult senior

Additional content available in CKB BOOST